Ahmed, SH; Biddle, K; Augustine, T; Azmi, S
(2020)
Post-Transplantation Diabetes Mellitus.
Diabetes Ther, 11 (4).
pp. 779-801.
ISSN 1869-6953
https://doi.org/10.1007/s13300-020-00790-5
SGUL Authors: Biddle, Kathryn
Abstract
Solid organ transplantation (SOT) is an established therapeutic option for chronic disease resulting from end-stage organ dysfunction. Long-term use of immunosuppression is associated with post-transplantation diabetes mellitus (PTDM), placing patients at increased risk of infections, cardiovascular disease and mortality. The incidence rates for PTDM have varied from 10 to 40% between different studies. Diagnostic criteria have evolved over the years, as a greater understating of PTDM has been reached. There are differences in pathophysiology and clinical course of type 2 diabetes and PTDM. Hence, managing this condition can be a challenge for a diabetes physician, as there are several factors to consider when tailoring therapy for post-transplant patients to achieve better glycaemic as well as long-term transplant outcomes. This article is a detailed review of PTDM, examining the pathogenesis, diagnostic criteria and management in light of the current evidence. The therapeutic options are discussed in the context of their safety and potential drug-drug interactions with immunosuppressive agents.
Item Type: |
Article
|
Additional Information: |
© The Author(s) 2020
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
Keywords: |
Calcineurin inhibitors, Diabetes mellitus, Graft failure, Macrovascular, Microvascular, Mortality, Post-transplantation, Rejection, Steroids, mTOR inhibitors, Calcineurin inhibitors, Diabetes mellitus, Graft failure, Macrovascular, Microvascular, Mortality, mTOR inhibitors, Post-transplantation, Rejection, Steroids |
SGUL Research Institute / Research Centre: |
Academic Structure > Infection and Immunity Research Institute (INII) |
Journal or Publication Title: |
Diabetes Ther |
ISSN: |
1869-6953 |
Language: |
eng |
Dates: |
Date | Event |
---|
April 2020 | Published | 24 February 2020 | Published Online |
|
Publisher License: |
Creative Commons: Attribution-Noncommercial 4.0 |
PubMed ID: |
32095994 |
Web of Science ID: |
WOS:000516458900001 |
![](http://static.pubmed.gov/portal/portal3rc.fcgi/2745237/img/27842) |
Go to PubMed abstract |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/113554 |
Publisher's version: |
https://doi.org/10.1007/s13300-020-00790-5 |
Statistics
Item downloaded times since 12 Aug 2021.
Actions (login required)
![Edit Item](/style/images/action_view.png) |
Edit Item |